Amneal Pharmaceuticals to Buy Kashiv BioSciences, Touts Strong Preliminary Q1 Results and Biosimilar Push

4 weeks ago 15

MarketBeat

Fri, April 24, 2026 astatine 9:35 AM CDT 6 min read

Amneal Pharmaceuticals logo

3 Lesser-Known Healthcare Names With Major Upside successful Store

Amneal Pharmaceuticals (NASDAQ:AMRX) outlined plans to get Kashiv BioSciences and reported preliminary first-quarter results during an capitalist call, with executives describing the woody arsenic a strategical determination to physique a vertically integrated biosimilars level and widen the company’s maturation illustration into the adjacent decade.

President and Co-CEO Chirag Patel said the Kashiv acquisition represents “a defining infinitesimal for Amneal,” and is intended to make “a afloat integrated planetary biosimilars leader.” Patel said the operation is designed to supply nonstop entree to what absorption characterized arsenic much than $300 cardinal of worldwide biologic nonaccomplishment of exclusivity implicit the adjacent decade, pairing Kashiv’s R&D and manufacturing capabilities with Amneal’s commercialized scale.

→ Amazon Stock Up 30%: Is AMZN Still a Buy Before Earnings?

6 reasons to bargain Teva Pharmaceuticals banal sooner than later

According to Patel, the transaction builds connected a concern betwixt the companies that has lasted much than a decade, which helium said reduces execution risk. He besides said the woody adds biosimilars arsenic a cardinal maturation pillar for Amneal’s “affordable medicines” strategy and diversifies the concern with a presumption toward extending maturation “well into 2030s.”

Co-CEO Chintu Patel said Kashiv is simply a biologics level built implicit 12 years with “more than $900 cardinal invested,” much than 600 employees, and 4 R&D and manufacturing sites spanning the U.S. and India. He said the level supports parallel improvement crossed modalities including monoclonal antibodies, fusion proteins, bispecifics, and cytokines.

→ Allbirds Exits Shoes, Pivots to AI With NewBird Rebrand

Chintu Patel said Kashiv’s cause substance capableness is expected to standard from 26,000 liters successful 2026 to 75,000 liters by 2028. In the Q&A, helium added that reaching that level is expected to necessitate astir $30 cardinal to $50 cardinal per twelvemonth of superior spending implicit the adjacent 2 to 3 years. Chirag Patel said cardinal molecules are expected to person 2 manufacturing sites (U.S. and India), with U.S. manufacturing a precedence for the company.

CFO Tasos Konidaris said Amneal structured the acquisition with $750 cardinal of upfront information divided 50/50 betwixt currency and equity. He said the equity constituent represents “approximately $29 cardinal of Amneal shares” and astir 8% dilution. The statement besides includes imaginable milestones of up to $350 cardinal tied to regulatory approvals, and imaginable royalties implicit 12 years contingent connected achieving definite gross nett levels. Amneal volition money Kashiv’s operations betwixt signing and closing, Konidaris said.

Read Entire Article